WASHINGTON: Researchers have unveiled new data that they said would help better assess breast or ovarian cancer risks in women, identifying the advantages of early detection and lifelong monitoring.
The study, published in the Journal of the American Medical Association (JAMA), involved nearly 10,000 women with the most common mutations -- 6,036 with BRCA1 and 3,820 with BRCA2.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.